Austrian deeptech startup Sarcura secures €7 million to revolutionize cell therapy manufacturing


The Austrian deeptech startup Sarcura just closed an oversubscribed €7 million Seed Plus funding round to develop a next-generation cell therapy manufacturing platform. Founded in 2019, Sarcura is developing an instrument platform for the manufacturing of advanced cell therapies. Their platform combines silicon chip technology and microfluidic processing to enable real-time process control and manipulation…

This content is for members only. Visit the site and log in/register to read.

The post Austrian deeptech startup Sarcura secures €7 million to revolutionize cell therapy manufacturing appeared first on EU-Startups.

Read More


Generated by Feedzy